Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month
Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.
Search
Experience our culture during your interview process
Discover if our company is the right fit for you.
Roger’s sarcoma experience
Our aspiration is to deliver more treatment options for people with cancer today, tomorrow and beyond. Roger, who lives with sarcoma, sheds light on why this is so important.
PharmD Advanced Pharmacy Practice Experiences Program
CAREER AREAS
The power of patient advocacy in cancer care
Patients and advocacy organizations agree that patient empowerment is key to quality cancer care
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Patient Centricity
Patient Centricity
Boehringer Cares Patient Assistance Portal
Click here to find out more about Boehringer Ingelheim's Boehringer Cares patient assistance program portal.
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Patient Week 2024 demonstrates importance of #PatientPoweredProgress
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients
Weill Cornell Medicine And Newyork-presbyterian Hospital Join Boehringer Ingelheim To Study The Incidence Of Progressive Interstitial Lung Disease In Covid-19 Patients
OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US
Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Leadership insights about our focus on patient centricity
Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD